Who we are

Who we are

We are a clinical stage immunology and inflammation focused company developing novel gene therapies and biologics and applying a systems approach to creating rational combination therapies that can significantly improve patients lives  

Leadership

Dr. Clement Leong, PhD, MBA:
Chief Executive Officer

Pharma/biotech/venture capital background in Australia and US (DNAX/ScheringPlough Biopharma, Entelos, SciVentures); led and completed multiple financings & successful clinical teams

Ph.D. from University of Western Australia; MBA from the Australian Graduate School of Management

Dr. Paul Weiden, MD:
Chief Medical Officer

Formerly a member of the University of Washington, Fred Hutchinson and Virginia Mason Medical Center

MD from Harvard Medical School

Dr. Geoffrey Pietersz, PhD:
VP. Technology Development

Formerly professor at the Burnet Institute, expert in bio-conjugation of therapeutics (e.g., vaccine; antibody drug conjugates)

Ph.D. from University of Melbourne

Dr Jacqui Waterkeyn,
Head Clin. Operations & Regulatory Affairs

Regulatory Affairs and Clinical Operations background (20+ years) in the Biotechnology and Pharmaceutical Industries, including Clinical Research Organisations

Ph. D. from the University of Melbourne

Board

Dr. Clement Leong, PhD, MBA:
Chief Executive Officer

Dr. Richard Stead, MD:
Non-Executive Director

Formerly Medical Director at Amgen & VP Clinical Res at Immunex; involved in approval of Epogen & Neupogen

MD from Stanford University; Postdoc training at the Brigham and Woman’s Hospital, Harvard Medical School

Dr. Jacques Banchereau, PhD:
Non-Executive Director

Currently Director of Immunological Sciences and the Deputy Director of JAX Genomic Medicine. Formerly Chief Scientific Officer of the Hoffmann-La Roche (Roche) & Director of the Baylor Institute for Immunology Research in Dallas, Texas.

Ph.D. University of Paris, France